Dilini Daswatta, DO
Nephrology · Lawrenceville, GANPI 1982992293
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $929 of the $1,091 with a category attached, or 85.1%. It is spread thinly across 13 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $471 and has fallen 98.6% since, to $7 in 2025. That places this record below the midpoint for nephrology clinicians in GA, where the typical reported total is $1,554.
Across 74 payments — averaging $14.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$213
- Amgen$203
- Otsuka America Pharmaceutical, Inc.$156
- AstraZeneca$114
- Akebia Therapeutics Inc$93
- Mallinckrodt Hospital Products Inc.$62
- plus $250 from 7 others
What the payments were for
- Food & beverage$92985%
- Education$16215%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 13 | $213 |
| Amgen(2 entities) | 16 | $203 |
| Otsuka America Pharmaceutical, Inc. | 5 | $156 |
| AstraZeneca(2 entities) | 7 | $114 |
| Akebia Therapeutics Inc | 8 | $93 |
| Mallinckrodt Hospital Products Inc. | 2 | $62 |
| Travere Therapeutics, Inc. | 13 | $57 |
| Daiichi Sankyo Inc. | 3 | $54 |
| Mallinckrodt Enterprises LLC | 2 | $51 |
| OPKO Pharmaceuticals, LLC | 2 | $39 |
| Shire North American Group Inc | 1 | $21 |
| GSK | 1 | $17 |
| Fresenius USA Marketing, Inc. | 1 | $11 |
How this compares
$1,091 in reported general payments places this provider in the 40th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 11 | $6,571 |
| Potassium Chloride | 21 | $1,068 |
| Nifedipine ErNifedipine | 12 | $300 |
| Losartan Potassium | 22 | $296 |
| Hydralazine Hcl | 13 | $221 |
| Lisinopril | 11 | $107 |
| Doxazosin Mesylate | 11 | $98 |
| Amlodipine Besylate | 15 | $92 |
| Furosemide | 12 | $83 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Lawrenceville
- James TumlinLawrenceville$434K
- William PaxtonLawrenceville$73K
- Sharad VirmaniLawrenceville$55K
- Lorin SanchezLawrenceville$23K
- Aakash AminLawrenceville$22K
- Kathryn ElmoreLawrenceville$12K
- Shaun ConlonLawrenceville$11K
- Nnamdi NwaohiriLawrenceville$11K
- Jusong ChoiLawrenceville$8K
- Sagar PanseMacon$542K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.